Akero Therapeutics, Inc. (AKRO)

Market Cap	1.55B
Revenue (ttm)	n/a
Net Income (ttm)	-179.27M
Shares Out	69.15M
EPS (ttm)	-3.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	408,069
Open	23.03
Previous Close	23.16
Day's Range	22.23 - 23.21
52-Week Range	11.25 - 53.77
Beta	-0.31
Analysts	Strong Buy
Price Target	41.43 (+85.12%)
Earnings Date	Aug 9, 2024

About AKRO

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manuf...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 56
• Stock Exchange: NASDAQ
• Ticker Symbol: AKRO

Analyst Forecast

According to 9 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is $41.43, which is an increase of 85.12% from the latest price.

Price Target

$41.43

(85.12% upside)

Analyst Consensus: Strong Buy